Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA.4 and BA.5 compared with previous waves in the Western Cape Province, South Africa
Objectives: We aimed to compare the clinical severity of Omicron BA.4/BA.5 infection with BA.1 and earlier variant infections among laboratory-confirmed SARS-CoV-2 cases in the Western Cape, South Africa, using timing of infection to infer the lineage/variant causing infection. Methods: We included public sector patients aged ≥20 years with laboratory-confirmed COVID-19 between May 01-May 21, 2022 (BA.4/BA.5 wave) and equivalent previous wave periods. We compared the risk between waves of (i) death and (ii) severe hospitalization/death (all within 21 days of diagnosis) using Cox regression adjusted for demographics, comorbidities, admission pressure, vaccination, and previous infection. Results: Among 3793 patients from the BA.4/BA.5 wave and 190,836 patients from previous waves, the risk of severe hospitalization/death was similar in the BA.4/BA.5 and BA.1 waves (adjusted hazard ratio [aHR] 1.12; 95% confidence interval [CI] 0.93; 1.34). Both Omicron waves had a lower risk of severe outcomes than previous waves. Previous infection (aHR 0.29, 95% CI 0.24; 0.36) and vaccination (aHR 0.17; 95% CI 0.07; 0.40 for at least three doses vs no vaccine) were protective. Conclusion: Disease severity was similar among diagnosed COVID-19 cases in the BA.4/BA.5 and BA.1 periods in the context of growing immunity against SARS-CoV-2 due to previous infection and vaccination, both of which were strongly protective..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:127 |
|---|---|
| Enthalten in: |
International Journal of Infectious Diseases - 127(2023), Seite 63-68 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mary-Ann Davies [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
BA.4 |
|---|
| doi: |
10.1016/j.ijid.2022.11.024 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ020801742 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ020801742 | ||
| 003 | DE-627 | ||
| 005 | 20230310215032.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijid.2022.11.024 |2 doi | |
| 035 | |a (DE-627)DOAJ020801742 | ||
| 035 | |a (DE-599)DOAJ8d9c951093f147fda08361f0e42bd294 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC109-216 | |
| 100 | 0 | |a Mary-Ann Davies |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA.4 and BA.5 compared with previous waves in the Western Cape Province, South Africa |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Objectives: We aimed to compare the clinical severity of Omicron BA.4/BA.5 infection with BA.1 and earlier variant infections among laboratory-confirmed SARS-CoV-2 cases in the Western Cape, South Africa, using timing of infection to infer the lineage/variant causing infection. Methods: We included public sector patients aged ≥20 years with laboratory-confirmed COVID-19 between May 01-May 21, 2022 (BA.4/BA.5 wave) and equivalent previous wave periods. We compared the risk between waves of (i) death and (ii) severe hospitalization/death (all within 21 days of diagnosis) using Cox regression adjusted for demographics, comorbidities, admission pressure, vaccination, and previous infection. Results: Among 3793 patients from the BA.4/BA.5 wave and 190,836 patients from previous waves, the risk of severe hospitalization/death was similar in the BA.4/BA.5 and BA.1 waves (adjusted hazard ratio [aHR] 1.12; 95% confidence interval [CI] 0.93; 1.34). Both Omicron waves had a lower risk of severe outcomes than previous waves. Previous infection (aHR 0.29, 95% CI 0.24; 0.36) and vaccination (aHR 0.17; 95% CI 0.07; 0.40 for at least three doses vs no vaccine) were protective. Conclusion: Disease severity was similar among diagnosed COVID-19 cases in the BA.4/BA.5 and BA.1 periods in the context of growing immunity against SARS-CoV-2 due to previous infection and vaccination, both of which were strongly protective. | ||
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Omicron | |
| 650 | 4 | |a BA.4 | |
| 650 | 4 | |a BA.5 | |
| 650 | 4 | |a Death, Severe hospitalization | |
| 653 | 0 | |a Infectious and parasitic diseases | |
| 700 | 0 | |a Erna Morden |e verfasserin |4 aut | |
| 700 | 0 | |a Petro Rousseau |e verfasserin |4 aut | |
| 700 | 0 | |a Juanita Arendse |e verfasserin |4 aut | |
| 700 | 0 | |a Jamy-Lee Bam |e verfasserin |4 aut | |
| 700 | 0 | |a Linda Boloko |e verfasserin |4 aut | |
| 700 | 0 | |a Keith Cloete |e verfasserin |4 aut | |
| 700 | 0 | |a Cheryl Cohen |e verfasserin |4 aut | |
| 700 | 0 | |a Nicole Chetty |e verfasserin |4 aut | |
| 700 | 0 | |a Pierre Dane |e verfasserin |4 aut | |
| 700 | 0 | |a Alexa Heekes |e verfasserin |4 aut | |
| 700 | 0 | |a Nei-Yuan Hsiao |e verfasserin |4 aut | |
| 700 | 0 | |a Mehreen Hunter |e verfasserin |4 aut | |
| 700 | 0 | |a Hannah Hussey |e verfasserin |4 aut | |
| 700 | 0 | |a Theuns Jacobs |e verfasserin |4 aut | |
| 700 | 0 | |a Waasila Jassat |e verfasserin |4 aut | |
| 700 | 0 | |a Saadiq Kariem |e verfasserin |4 aut | |
| 700 | 0 | |a Reshma Kassanjee |e verfasserin |4 aut | |
| 700 | 0 | |a Inneke Laenen |e verfasserin |4 aut | |
| 700 | 0 | |a Sue Le Roux |e verfasserin |4 aut | |
| 700 | 0 | |a Richard Lessells |e verfasserin |4 aut | |
| 700 | 0 | |a Hassan Mahomed |e verfasserin |4 aut | |
| 700 | 0 | |a Deborah Maughan |e verfasserin |4 aut | |
| 700 | 0 | |a Graeme Meintjes |e verfasserin |4 aut | |
| 700 | 0 | |a Marc Mendelson |e verfasserin |4 aut | |
| 700 | 0 | |a Ayanda Mnguni |e verfasserin |4 aut | |
| 700 | 0 | |a Melvin Moodley |e verfasserin |4 aut | |
| 700 | 0 | |a Katy Murie |e verfasserin |4 aut | |
| 700 | 0 | |a Jonathan Naude |e verfasserin |4 aut | |
| 700 | 0 | |a Ntobeko A.B. Ntusi |e verfasserin |4 aut | |
| 700 | 0 | |a Masudah Paleker |e verfasserin |4 aut | |
| 700 | 0 | |a Arifa Parker |e verfasserin |4 aut | |
| 700 | 0 | |a David Pienaar |e verfasserin |4 aut | |
| 700 | 0 | |a Wolfgang Preiser |e verfasserin |4 aut | |
| 700 | 0 | |a Hans Prozesky |e verfasserin |4 aut | |
| 700 | 0 | |a Peter Raubenheimer |e verfasserin |4 aut | |
| 700 | 0 | |a Liezel Rossouw |e verfasserin |4 aut | |
| 700 | 0 | |a Neshaad Schrueder |e verfasserin |4 aut | |
| 700 | 0 | |a Barry Smith |e verfasserin |4 aut | |
| 700 | 0 | |a Mariette Smith |e verfasserin |4 aut | |
| 700 | 0 | |a Wesley Solomon |e verfasserin |4 aut | |
| 700 | 0 | |a Greg Symons |e verfasserin |4 aut | |
| 700 | 0 | |a Jantjie Taljaard |e verfasserin |4 aut | |
| 700 | 0 | |a Sean Wasserman |e verfasserin |4 aut | |
| 700 | 0 | |a Robert J. Wilkinson |e verfasserin |4 aut | |
| 700 | 0 | |a Milani Wolmarans |e verfasserin |4 aut | |
| 700 | 0 | |a Nicole Wolter |e verfasserin |4 aut | |
| 700 | 0 | |a Andrew Boulle |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t International Journal of Infectious Diseases |d Elsevier, 2015 |g 127(2023), Seite 63-68 |w (DE-627)DOAJ000043923 |x 18783511 |7 nnns |
| 773 | 1 | 8 | |g volume:127 |g year:2023 |g pages:63-68 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ijid.2022.11.024 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/8d9c951093f147fda08361f0e42bd294 |z kostenfrei |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S1201971222006154 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1201-9712 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 127 |j 2023 |h 63-68 | ||